USAID’s Reaching Impact Saturation and Epidemic Control (RISE) program assists countries to respond to the HIV and COVID-19 pandemics, providing technical assistance, service delivery, research, and cross-cutting health system support to address critical HIV and COVID-19 pandemic response priorities. All data shared are cumulative, unless otherwise noted.

RISE programming has addressed challenges in 22 countries:
- HIV response supported in 14 countries
- COVID-19 response supported in 15 countries
- COVID-19 Test-to-Treat programming in 5 countries
- HIV technical assistance provided in 8 countries
- Hosting HIV and/or HPV prevention research studies 2 countries

RISE by the Numbers
As of October 2022

HIV
- 69,825 people diagnosed with HIV through RISE testing services
- 99.3% of clients testing positive linked to antiretroviral therapy services
- 156,133 people provided with lifesaving ART across 2 countries (Burundi and Nigeria in FY22)
- 96.7% of clients on ART are virally suppressed (FY22)

COVID
- 10,289,433 COVID-19 vaccines administered
- 1,781 facilities supported with COVID-19 case management technical assistance
- 14 RISE-supported PSA plants for medical oxygen generation
- 16,470 health workers trained on COVID-19 related IPC and/or WASH
- 53,338 health workers trained on COVID-19 case management
- 16 national policies, protocols, or guidelines developed or adapted with USG and RISE support
- 56,033 clients provided with Voluntary Medical Male Circumcision for HIV prevention
- 28,084 RISE clients currently using PrEP
- 156,133 people provided with lifesaving ART across 2 countries (Burundi and Nigeria in FY22)
- 28,084 RISE clients currently using PrEP

This briefer was made possible through the United States Agency for International Development funded RISE program under the terms of the cooperative agreement 7200AA19CA00003. The contents are the responsibility of the RISE program and do not necessarily reflect the views of USAID or the United States Government.